China’s Bio-Thera has struck a licensing deal with Biomm that will give the Brazilian company exclusive rights to market the BAT1706 bevacizumab biosimilar in its home market.
China’s Bio-Thera Solutions has struck a licensing deal with Brazil’s Biomm that will give the Brazilian firm exclusive rights to market Bio-Thera’s BAT1706 proposed biosimilar version of Avastin (bevacizumab) in its domestic market.
“Biomm will have exclusive rights to distribute and market the drug in Brazil,” the Chinese company confirmed, indicating that Biomm...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
